HC Wainwright Issues Positive Forecast for IPA Earnings

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) – Equities researchers at HC Wainwright increased their Q3 2025 EPS estimates for ImmunoPrecise Antibodies in a report issued on Wednesday, December 11th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.06) per share for the quarter, up from their prior estimate of ($0.07). HC Wainwright currently has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for ImmunoPrecise Antibodies’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for ImmunoPrecise Antibodies’ FY2025 earnings at ($0.27) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.02) EPS, Q4 2026 earnings at ($0.01) EPS, FY2026 earnings at ($0.13) EPS and FY2027 earnings at $0.04 EPS.

ImmunoPrecise Antibodies Price Performance

Shares of IPA stock opened at $0.40 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.82 and a current ratio of 0.99. ImmunoPrecise Antibodies has a fifty-two week low of $0.32 and a fifty-two week high of $2.60. The firm has a market cap of $11.63 million, a P/E ratio of -0.52 and a beta of 0.06. The business’s 50 day moving average price is $0.47 and its 200-day moving average price is $0.72.

ImmunoPrecise Antibodies (NASDAQ:IPA) last announced its quarterly earnings results on Monday, September 16th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). ImmunoPrecise Antibodies had a negative net margin of 114.50% and a negative return on equity of 70.69%. The business had revenue of $3.85 million for the quarter, compared to analysts’ expectations of $4.96 million.

Institutional Investors Weigh In On ImmunoPrecise Antibodies

A hedge fund recently raised its stake in ImmunoPrecise Antibodies stock. Renaissance Technologies LLC lifted its stake in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 70.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 63,910 shares of the company’s stock after buying an additional 26,310 shares during the quarter. Renaissance Technologies LLC owned about 0.24% of ImmunoPrecise Antibodies worth $65,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 6.70% of the company’s stock.

ImmunoPrecise Antibodies Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.